Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues

Pancreas

Volumn 42, Issue 4, 2013, Pages 707-716

  Mohelnikova Duchonova, Beatrice ^a,b   Brynychova, Veronika ^a,c   Oliverius, Martin ^d   Honsova, Eva ^d   Kala, Zdenek ^e   Muckova, Katarina ^e   Soucek, Pavel ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

ABC transporters; carcinoma; expression; KRAS; pancreas

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ABCA4 PROTEIN; ABCB2 PROTEIN; ABCB3 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW;

AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, PANCREATIC DUCTAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84876880512     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318279b861     Document Type: Review

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225-249.
2. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53(4): 549-554.
3. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993; 143(2): 545-554.
4. Maitra A, Fukushima N, Takaori K, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005; 12: 81-91.
5. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6: 2969-2972.
6. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001; 25: 579-586.
7. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendation. Cancer Res. 2006; 66: 95-106.
8. Kojima K, Vickers SM, Adsay NV, et al. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Res. 2007; 67: 8121-8130.
9. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(31): 4113-4120.
10. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004; 363(9414): 1049-1057.
11. Wong HH, Lemoine NR. Pancreatic cancer: Molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009; 6(7): 412-422.
12. Abbruzzese JL. Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality. Semin Oncol. 2002; 29: 2-8.
13. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
14. Mohelnikova-Duchonova B, Soucek P. The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine and erlotinib. In: Watanabe HS, ed. Horizons in Cancer Research, Volume 46. New York, NY: NOVA Science Publishers Inc; 2012. http: //nutrigene.4t.com/humanabc.htm. Accessed October 6, 2010.
15. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis. 2012; 27(2): 187-196.
16. Arrese M, Ananthanarayanan M. The bile salt export pump: Molecular properties, function and regulation. Pflugers Arch. 2004; 449(2): 123-131.
17. Chen HL, Gabrilovich D, Tampé R, et al. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet. 1996; 13(2): 210-213.
18. Kasajima A, Sers C, Sasano H, et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol. 2010; 41: 1758-1769.
19. Shichijo S, Ishihara Y, Azuma K, et al. ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients. Oncol Rep. 2005; 13: 907-913.
20. Greene FL, Trotti A III, Fritz AG, et al. In: Edge SB, ed. AJCC Cancer Staging Handbook. 7th ed. Chicago, Ill: American Joint Committee on Cancer; 2009; 2010.
21. Soucek P, Anzenbacher P, Skoumalova I, et al. Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells. 2005; 23: 1417-1422.
22. Topic E, Gluhak J. Isolation of restrictible DNA. Eur J Clin Chem Clin Biochem. 1991; 29: 327-330.
23. Mohelnikova-Duchonova B, Oliverius M, Honsova E, et al. Evaluation of reference genes and normalization strategy for quantitative real-time PCR in human pancreatic carcinoma. Dis Markers. 2012; 32(3): 203-210.
24. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines, minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55: 611-622.
25. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006; 6: 295.
26. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in realtime PCR. Nucleic Acids Res. 2000; 30: E36.
27. Wolff RA. Chemotherapy for pancreatic cancer: From metastatic disease to adjuvant therapy. Cancer J. 2007; 13: 475-479.
28. König J, Hartel M, Nies AT, et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer. 2005; 115(3): 359-367.
29. Auner V, Sehouli J, Oskay-Oezcelik G, et al. ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol. 2010; 117(2): 198-201.
30. Lo M, Tsao MS, Hedley D, et al. Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. Pancreas. 2009; 38: 85-93.
31. Zhou H, Li C, Li J, et al. Associations of ATP-binding cassette transporter A1 and G1 with insulin secretion in human insulinomas. Pancreas. 2012; 41(6): 934-939.
32. Sturek JM, Castle D, Trace AP, et al. An intracellular role of ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic A cells. J Clin Invest. 2010; 120(7): 2575-2589.
33. Mauldin JP, Nagelin MH, Wojcik AJ, et al. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation. 2008; 117(21): 2785-2792.
34. Kruit JK, Wijesekara N, Fox JE, et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 2011; 60(12): 3186-3196.
35. Rao KN, Kottapally S, Shinozuka H. Lipid composition and 3-hydroxy 3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas. Biochim Biophys Acta. 1983; 759: 74-80.
36. Rao KN, Kottapally S, Shinozuka H. Acinar cell carcinoma of rat pancreas: Mechanism of deregulation of cholesterol metabolism. Toxicol Pathol. 1984; 12(1): 62-68.
37. Kaminski WE, Piehler A, Wenzel JJ. ABC A-subfamily transporters: Structure, function and disease. Biochim Biophys Acta. 2006; 1762: 510-524.
38. Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004; 350: 1296-1303.
39. Bergen AA, Plomp AS, Schuurman EJ, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet. 2000; 25(2): 228-231.
40. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science. 1989; 245(4922): 1066-1073.
41. Naren AP, Quick MW, Collawn JF, et al. Syntaxin 1A inhibits CFTR chloride channels by means of domain-specific protein-protein interactions. Proc Natl Sci U S A. 1998; 95: 10972-10977.
42. Hanrahan JW, Mathews CJ, Grygorczyk R, et al. Regulation of the CFTR chloride channel from human and sharks. J Exp Zool. 1996; 275: 283-291.
43. Weixel KM, Bradbury NA. The carboxyl terminus of the cystic fibrosis transmembrane conductance regulator binds to AP-2 clathrin adaptors. J Biol Chem. 2000; 275: 3655-3660.
44. Nichols CG, Shyng SL, Nestorowicz A, et al. Adenosine diphosphate as an intracellular regulator of insulin secretion. Science. 1996; 272: 1785-1787.
45. Bennett K, James C, Hussain K. Pancreatic A-cell KATP channels: Hypoglycaemia and hyperglycaemia. Rev Endocr Metab Disord. 2010; 11(3): 157-163.
46. Barbet R, Peiffer I, Hutchins JR, et al. Expression of the 49 human ATP binding cassette (ABC) genes in pluripotent embryonic stem cells and in early- and late-stage multipotent mesenchymal stem cells: Possible role of ABC plasma membrane transporters in maintaining human stem cell pluripotency. Cell Cycle. 2012; 11(8) : 1611-1620.
47. Rudloff U, Bhanot U, Gerald W, et al. Biobanking of human pancreas cancer tissue: Impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol. 2010; 17: 2229-2236.